Format

Send to

Choose Destination
J Control Release. 2017 Jun 28;256:79-91. doi: 10.1016/j.jconrel.2017.04.012. Epub 2017 Apr 12.

PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo.

Author information

1
Sys2Diag, CNRS UMR 9005/ALCEDIAG, 1682 Rue de la Valsière, 34184 Montpellier Cedex 4, France.
2
Centre de Recherche de Biologie cellulaire de Montpellier, CNRS UMR 5237, 1919 Route de Mende, 34293 Montpellier Cedex 5, France.
3
Microscopie Electronique et Analytique, Université de Montpellier, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France.
4
EA 7435 IMOTION (Imagerie moléculaire et thérapies innovantes en oncologie), Université de Bordeaux, 146 rue Leo Saignat, 33076 Bordeaux, France.
5
Centre de Biochimie Structurale, CNRS UMR 5048, Inserm U1054, Université de Montpellier, 29 rue de Navacelles, 34090 Montpellier, France.
6
Institut des Biomolécules Max Mousseron, CNRS UMR 5247, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France.
7
Institut de Génomique Fonctionnelle, CNRS UMR 5203, Inserm U661, Université de Montpellier, 141 Rue de la Cardonille, 34094 Montpellier Cedex 5, France.; Laboratory of Excellence Ion Channel Science and Therapeutics, F-06560 Valbonne.
8
Centre de Recherche de Biologie cellulaire de Montpellier, CNRS UMR 5237, 1919 Route de Mende, 34293 Montpellier Cedex 5, France. Electronic address: prisca.boisguerin@crbm.cnrs.fr.

Abstract

Small interfering RNAs (siRNAs) present a strong therapeutic potential because of their ability to inhibit the expression of any desired protein. Recently, we developed the retro-inverso amphipathic RICK peptide as novel non-covalent siRNA carrier. This peptide is able to form nanoparticles (NPs) by self-assembling with the siRNA resulting in the fully siRNA protection based on its protease resistant peptide sequence. With regard to an in vivo application, we investigated here the influence of the polyethylene glycol (PEG) grafting to RICK NPs on their in vitro and in vivo siRNA delivery properties. A detailed structural study shows that PEGylation did not alter the NP formation (only decrease in zeta potential) regardless of the used PEGylation rates. Compared to the native RICK:siRNA NPs, low PEGylation rates (≤20%) of the NPs did not influence their cellular internalization capacity as well as their knock-down specificity (over-expressed or endogenous system) in vitro. Because the behavior of PEGylated NPs could differ in their in vivo application, we analyzed the repartition of fluorescent labeled NPs injected at the one-cell stage in zebrafish embryos as well as their pharmacokinetic (PK) profile after administration to mice. After an intra-cardiac injection of the PEGylated NPs, we could clearly determine that 20% PEG-RICK NPs reduce significantly liver and kidney accumulation. NPs with 20% PEGylation constitutes a modular, easy-to-handle drug delivery system which could be adapted to other types of functional moieties to develop safe and biocompatible delivery systems for the clinical application of RNAi-based cancer therapeutics.

KEYWORDS:

Cell penetrating peptides; Gene knock-down; Nanoparticle; PEGylation; Retro-inverso; siRNA delivery

PMID:
28411182
DOI:
10.1016/j.jconrel.2017.04.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center